Pharmacological evidence for heterogeneity of ocular $aL₂ adrenoceptors

References

• Bylund D. B. Heterogeneity of α2 adrenergic receptors. Pharmacol. Biochem. Behav. 1985; 22: 835–843
   PubMed Web of Science ®Google Scholar
• Neylon C. B., Summers R. J. [3H]Rauwolscine binding to α2-adrenoceptors in the mammalian kidney: apparent receptor heterogeneity between species. Br. J. Pharmacol 1985; 85: 349–359
   PubMed Web of Science ®Google Scholar
• Alabaster V. A, Keir R. F., Peters C. J. Comparison of potency of α2-adrenoceptor agonists in vitro: evidence for heterogeneity of α2-adrenoceptors. Br. J. Pharmacol. 1986; 88: 607–614
   PubMed Web of Science ®Google Scholar
• Boyajian C. L., Leslie F. M. Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: differential binding properties of [3H]Rauwolscine and [3H]dazoxan in rat brain. J. Pharmacol. Exp. Ther. 1987; 241: 1092–1098
   PubMed Web of Science ®Google Scholar
• Bylund D. B., Ray-Prenger C. Alpha-2A and Alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype. J. Pharmacol. Exp. Ther. 1989; 251: 640–644
   PubMed Web of Science ®Google Scholar
• Regan J. W, Kobilka T. S, Pang-Feng T. L., Caron M. G, Lefkowitz R. J., Kobilka B. S. Cloning and expression of a human kidney cDNA for an α2-adrenergic receptor subtype. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 6301–6305
   PubMed Web of Science ®Google Scholar
• Ruffolo R. R, Jr., Sulpizio A. C, Nichols A. J, DeMarinis R. M., Heible J. P. Pharmacologic differentiation between pre- and post junctional α2-adrenoceptors by SKSF 104078. Naunyn. Schmiedebergs Arch. Pharmacol. 1987; 336: 415–418
   PubMedGoogle Scholar
• Daly R. N, Sulpizio A. C, Levitt B., DeMarinis R. M, Regan J. W, Ruffolo R. R, Jr., Hieble J. P. Evidence for heterogeneity between pre- and post junctional alpha-2-adrenoceptors using 9-substituted 3-benzazepines. J. Pharmacol. Exp. Ther. 1988; 247: 122–128
   PubMed Web of Science ®Google Scholar
• Heible J. P, Sulpizio A. C, Nichols A. J, Willett R. N., Ruffolo R. R, Jr. Pharmacologic characterization of SK&F 104078, a novel alpha-2 adrenoceptor antagonist which discriminates between pre- and post junctional alpha-2 adrenoceptors. J. Pharmacol. Exp. Ther. 1988; 24: 645–652
   Google Scholar
• Akers I., Coates J., Drew G. M., Sullivan A. T. Antagonist profile of SKSF 104078 at pre- and post junctional α2-adrenoceptors. Br. J. Pharmacol. 1989; 94: 433P
   Google Scholar
• Makabe R. Ophthalmological studies with dichlorophenyamines-imidazolines. . Dtsch. Med. Wochenschr. 1966; 91: 1686–1696
   PubMedGoogle Scholar
• Hasslinger C. Catapres (2-[2, 6-dichlorophenylamino]-2-imidazoline hydrochloride) — a new drug lowering intraocular pressure. Klin. Mbl. Augenheilk. 1969; 154: 95–105
   PubMedGoogle Scholar
• Lee D. A, Topper J. E., Brubaker R. F. Effect of clonidine on aqueous humor flow in normal human eyes. Exp. Eye Res. 1984; 38: 239–246
   PubMed Web of Science ®Google Scholar
• Gharagozloo N. Z, Relf S. J., Brubaker R. F. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology 1988; 95: 1217–1220
   PubMed Web of Science ®Google Scholar
• Mittag T. W., Tormay A. Drug responses of adenylate cyclase in irisciliary body determined by adenine labeling. Invest Ophthalmol. Vis. Sci. 1985; 26: 396–399
   PubMed Web of Science ®Google Scholar
• Bausher L. P, Gregory D. S., Sears M. L. Interaction between alpha2 and beta2-adrenergic receptors in rabbit ciliary processes. Curr. Eye Res. 1987; 6: 497–505
   PubMed Web of Science ®Google Scholar
• Kintz P., Himber J., deBurlet G., Andermann G. Characterization of alpha2-adrenergic receptors, negatively coupled to adenylate cylase, in rabbit ciliary processes. Curr. Eye Res. 1988; 7: 287–292
   PubMed Web of Science ®Google Scholar
• Burke J. A., Potter D. A. Ocular effects of a relatively selective α2 agonist (UK-14, 304–18) in cats, rabbits, and monkeys. Curr. Eye Res. 1986; 5: 665–676
   PubMed Web of Science ®Google Scholar
• Burke J. A., Potter D. E. The ocular effects of xylazine in rabbits, cats and monkeys. J. Ocular Pharmacol. 1986; 2: 9–22
   PubMedGoogle Scholar
• Burke J. A., Crosson C. E., Potter D. E. Can UK 14,304–18 lower IOP by a peripheral mechanism? Curr. Eye Res. 1989; 8: 547–552
   Google Scholar
• Potter D. E., Ogidigben M. J. Medetomidine-induced alterations in intraocular pressure and contraction of the nicitatiing membrane. Invest. Ophthalmol. Vis. Sci. 1992; 32: 2799–2805
   Google Scholar
• Potter D. E., Burke J. A. An in vivo model for dissociatiating alpha-2 and DA-2 adrenoceptor activity in ocular adnexa: utility of the cat nictitating membrane preparation. Curr. Eye Res. 1984; 3: 1289–1298
   PubMed Web of Science ®Google Scholar
• Crosson C. E, Burke J. A, Chan M. F., Potter D. E. Prejunctional adrenoceptor activity of N-0437: a relatively selective DA2 dopamine receptor agonist. Eur. J. Pharmacol. 1990; 178: 351–355
   PubMed Web of Science ®Google Scholar
• Bylund D. B. Comparison of [3H] clonidine and [3 H] yohimbine binding: Possible subtypes of alpha-2 adrenergic receptors. Pharmacologist 1981; 23: 215–217
   Google Scholar
• Bylund D. B. Subtypes of α2-adrenoceptors: pharmacological and molecular biological evidence converge. TIPS 1988; 9: 356–361
   PubMed Web of Science ®Google Scholar
• Heible J. P, Sulpizio A. C, Nichols A. J, DeMarinis R. M, Pfeiffer F. R, Lavanchy P. G., Ruffolo R. R, Jr. Pharmacological differentiation of pre- and post junctional α2-adrenoceptors. J. Hyperten. 1987; 4, (Suppl. 6): 5189–5192
   Google Scholar
• Jumblatt J. E, Liu J. G., North G. T. Alpha-2 adrenergic modulation of norepinephrine secretion in the perfused rabbit iris/ciliary body. Curr. Eye Res. 1987; 6: 767–777
   PubMed Web of Science ®Google Scholar
• Akers I., Coates J., Drew G. M., Sullivan A. T. α2-adrenoceptor blocking profile of SK&F 104078: further evidence for receptor subtypes. Br. J. Pharmacol. 1991; 102: 943–949
   PubMed Web of Science ®Google Scholar
• Heible J. P, Sulpizio A. C, Gutzait L., Gombar C. T. Cardiovascular effects of SK&F 104078, a novel α2-adrenoceptor agonist, in normotensive and hypertensive rats. . J. Cardiovasc. Pharmacol 1990; 15: 845–852
   PubMed Web of Science ®Google Scholar
• Michel M. D., Insel P. A. Are there multiple imidazoline binding sites?. TIPS 1989; 10: 342–344
   PubMed Web of Science ®Google Scholar
• Walters T. R, Repass R. L, Sargent J. P, Kelley E. P, Stoecker J. F, Chen K. S., Harper D. G. A pilot study of the efficacy and safety of AGN 190342-LF 0.02% and 0.08% in patients with elevated intraocular pressure. Invest. Ophthalmol. Vis. Sci. 1991; 32(suppl)988
   Google Scholar